Ricevi le ultime notizie sulle azioni Inventiva con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di IVA

Ultime notizie per

INVENTIVA SA - ADR

Inventiva

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Inventiva S.A. - American Depository Shares

Inventiva SA

Alpha Architect International Quantitative Value ETF

Invesco AT1 Capital Bond UCITS ETF - USD Acc

INVESTCORP AI ACQ CRP UTS by Investcorp AI Acquisition Corp.

Investcorp AI Acquisition Corp

Investcorp AI Acquisition Corp Warrants (01/06/2028)

News

Press Releases

Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease

Inventiva receives $10 million milestone payment from CTTQ

Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance

Inventiva Reports Preliminary 2025 First-Half Financial Information¹

Half-Year Review of Inventiva's Liquidity Contract with  Kepler Cheuvreux

Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

Inventiva to Participate in Upcoming September Investor Conferences

Inventiva to Host Analyst and Investor Event on October 8, 2025

Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update

Inventiva Appoints Andrew Obenshain as Chief Executive Officer

IVEVF

PARIS:IVA

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma

AnaptysBio

ArriVent BioPharma

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

BridgeBio Oncology Therapeutics, Inc. - Common Stock

BridgeBio Oncology

Bicara Therapeutics

CareDx

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Geron

Immunome

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Kura Oncology

MiMedx Group

Nanobiotix

Olema Pharmaceuticals, Inc. - Common Stock

Comments

Inventiva Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO